myriad_S_stacked.png
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
November 04, 2024 08:39 ET | Myriad Genetics, Inc.
Myriad Genetics comments on UnitedHealthcare’s updated medical policy for pharmacogenetic testing
myriad_S_stacked.png
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
October 30, 2024 08:00 ET | Myriad Genetics, Inc.
Myriad Genetics, Inc. (NASDAQ: MYGN) will hold its third quarter earnings conference call on Thursday, Nov. 7, 2024 at 4:30 pm ET.
myriad_S_stacked.png
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
October 16, 2024 09:00 ET | Myriad Genetics, Inc.
Myriad Genetics announced a strategic partnership with jscreen to advance health equity and genetic testing access.
myriad_S_stacked.png
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
October 15, 2024 09:00 ET | Myriad Genetics, Inc.
Myriad Genetics and Flatiron Health partner to make genetic testing more accessible with EMR integration
myriad_S_stacked.png
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
October 08, 2024 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research...
myriad_S_stacked.png
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
October 03, 2024 09:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a...
myriad_S_stacked.png
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
October 01, 2024 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and...
myriad_S_stacked.png
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
September 18, 2024 08:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will showcase 10 studies highlighting...
myriad_S_stacked.png
Myriad Genetics to Host Investor Event on October 9, 2024
September 05, 2024 08:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Event at the Westin Grand Central...
myriad_S_stacked.png
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
August 21, 2024 08:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two...